Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
Phase III study did not meet its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications (death, mechanical ventilation or ICU care)
1
Detailed results will be submitted for publication to support scientific understanding of JAK inhibition in COVID-19 and inform ongoing research
Novartis commitment to address COVID-19 pandemic remains strong with multiple research collaboration initiatives ongoing
Basel, December 14, 2020 Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint
Dec 14, 2020 06:15 UTC
Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm WILMINGTON, Del. (Business Wire) Incyte (Nasdaq:INCY) today announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi
®), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did not meet its primary endpoint. Initial data show that there was no reduction in the proportion of patients receiving ruxolitinib plus SoC who experienced severe complications including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit (ICU) care by Day 29, compared to SoC treatment alone (12.0% vs. 11.8% [OR: 0.91 [95% CI: 0.48-1.73],